These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
263 related articles for article (PubMed ID: 32562246)
1. PARP inhibition suppresses the emergence of temozolomide resistance in a model system. Yuan AL; Meode M; Tan M; Maxwell L; Bering EA; Pedersen H; Willms J; Liao J; Black S; Cairncross JG; Blough MD J Neurooncol; 2020 Jul; 148(3):463-472. PubMed ID: 32562246 [TBL] [Abstract][Full Text] [Related]
2. PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma. Wu S; Li X; Gao F; de Groot JF; Koul D; Yung WKA Neuro Oncol; 2021 Jun; 23(6):920-931. PubMed ID: 33433610 [TBL] [Abstract][Full Text] [Related]
3. Restoration of Temozolomide Sensitivity by PARP Inhibitors in Mismatch Repair Deficient Glioblastoma is Independent of Base Excision Repair. Higuchi F; Nagashima H; Ning J; Koerner MVA; Wakimoto H; Cahill DP Clin Cancer Res; 2020 Apr; 26(7):1690-1699. PubMed ID: 31900275 [TBL] [Abstract][Full Text] [Related]
4. Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide. Tentori L; Ricci-Vitiani L; Muzi A; Ciccarone F; Pelacchi F; Calabrese R; Runci D; Pallini R; Caiafa P; Graziani G BMC Cancer; 2014 Mar; 14():151. PubMed ID: 24593254 [TBL] [Abstract][Full Text] [Related]
5. Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts. Gupta SK; Mladek AC; Carlson BL; Boakye-Agyeman F; Bakken KK; Kizilbash SH; Schroeder MA; Reid J; Sarkaria JN Clin Cancer Res; 2014 Jul; 20(14):3730-41. PubMed ID: 24838527 [TBL] [Abstract][Full Text] [Related]
17. Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype. Teng J; Hejazi S; Hiddingh L; Carvalho L; de Gooijer MC; Wakimoto H; Barazas M; Tannous M; Chi AS; Noske DP; Wesseling P; Wurdinger T; Batchelor TT; Tannous BA Neuro Oncol; 2018 Apr; 20(5):642-654. PubMed ID: 29099956 [TBL] [Abstract][Full Text] [Related]
18. Acquired temozolomide resistance in human glioblastoma cell line U251 is caused by mismatch repair deficiency and can be overcome by lomustine. Stritzelberger J; Distel L; Buslei R; Fietkau R; Putz F Clin Transl Oncol; 2018 Apr; 20(4):508-516. PubMed ID: 28825189 [TBL] [Abstract][Full Text] [Related]
19. SNAP reverses temozolomide resistance in human glioblastoma multiforme cells through down-regulation of MGMT. Tsai CK; Huang LC; Wu YP; Kan IY; Hueng DY FASEB J; 2019 Dec; 33(12):14171-14184. PubMed ID: 31725331 [TBL] [Abstract][Full Text] [Related]
20. Preconditioning with INC280 and LDK378 drugs sensitizes MGMT-unmethylated glioblastoma to temozolomide: Pre-clinical assessment. Das A; Alshareef M; Porto GBF; Infinger LK; Vandergrift WA; Lindhorst SM; Varma AK; Patel SJ; Cachia D J Neurol Sci; 2020 Nov; 418():117102. PubMed ID: 32866816 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]